

June 1, 2021

Dear Dean Health Plan Provider:

Dean Health Plan's Medical Policy Committee has approved the drug policies highlighted in this notification. These changes, and other changes not included in this notification, will also be communicated in the quarterly provider newsletters and available online. Please share this information with others within your organization who may be affected by these changes.

Dean Health Plan requires providers to obtain prior authorization on all drugs with written policies by sending authorization requests to Navitus, unless otherwise noted in the policy. Please note that most drugs require specialists to prescribe and request authorization.

### **New Drug Policy**

Effective for dates of service on and after September 1, 2021, the following will require approved authorization through Navitus:

- Medically Administered Oncology Products, MB2112 — new overarching oncology policy replacing most of the individual policies. Prior authorization is required and is restricted to oncology prescribers.

### **Changes to Drug Policy**

Effective for dates of service on and after September 1, 2021, the following will be changed:

- SPRAVATO (esketamine), MB1921 — removal of psychiatric nurse practitioner from allowed prescriber and adding Electro Convulsive Therapy as a step. Prior authorization is required and is restricted to psychiatrist prescribers.

### **Retired Drug Policies**

Effective September 1, 2021, the drug policies listed below will be retired, but **not** the drugs themselves. The policies for the following drugs will be included under the medical policy titled "Medically Administered Oncology Products," MB2112:

- ABRAXANE (paclitaxel albumin-bound), MB1801
- ADCETRIS (brentuximab-vedotin), MB1945
- ALIMTA (pemetrexed for injection), MB1837
- BELEODAQ (belinostat), MB2100
- Bendamustine Products, MB1917
- BLINCYTO-blinatumomab, MB2101
- CYRAMZA (ramucirumab), MB1918
- EMLICITI (elotuzumab), MB1906
- ENHERTU (fam trastuzumab deruxtecan nxki), MB2007
- Monjuvi (afasitamab-CXIX), MB2016
- PADCEV (enfortumab vedotin-ejfv), MB2010
- SARCLISA (isatuximab), MB2004
- TRODELVY (sacituzumab govitecan), MB2009
- VECTIBIX (panitumumab), MB1810
- VELCADE (bortezomib), MB1922

The Medically Administered Oncology Products policy, MB2112, will be published in the Dean Health Plan Document Library in early June 2021. The policy also will be available through the

Medical Injectable List which also lists other oncology drug policies, separate from MB2112, and in the individual PA forms on the Navitus Prescriber portal.

### **Medical Benefit Drug Policies**

Prescribers are encouraged to track changes and review policies in their entirety. Medical benefit drug policies are accessible online via the Dean Health Plan Document Library at [deancare.com/document-repository](http://deancare.com/document-repository) or by visiting [deancare.com](http://deancare.com) and following the step-by-step instructions below:

- Select the drop down from the **I AM A...** screen to **Provider**.
- Navigate to **Pharmacy Services**.
- Under **Up to date Drug Policies**, click **See library**.
- Enter the drug name or the numerical digits of the assigned policy number (e.g. entering 1234 of the medical benefit policy number MB1234) in the **Search for** field to find the full catalog of drug policies.

Criteria for pharmacy benefit medications may be found on the associated prior authorization form located in the Provider Portal.

Please email any questions to [DHPPharmacyServices@deancare.com](mailto:DHPPharmacyServices@deancare.com).

Sincerely,  
Dean Health Plan Pharmacy Services